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Timing is everything! Appropriate timing of treatment is 
the key to successful intensive care; treatment that is 
delayed could be as detrimental as treatment that is 
premature. Th  erefore, Lange and colleagues [1], in this 
issue of Critical Care, reported on the time course of the 
expression of the diﬀ  erent isoforms of the nitric oxide 
synthase (NOS) – that is, neuronal NOS [nNOS], 
inducible NOS [iNOS], and endothelial NOS [eNOS] 
(also known as NOS1, NOS2, and NOS3, respectively) – 
of the tissue levels of nitrotyrosine and poly(ADP-ribose), 
markers of nitrosative stress, and DNA damage resulting 
from peroxynitrite formation as well as p65, a mirror of 
the activation of the nuclear factor-kappa-B (NF-κB), in a 
well-established resuscitated ovine model of septic shock 
induced by Pseudomonas aeruginosa pneumonia. 
‘Downstream eﬀ  ects’ were evaluated by measuring NOS 
activity, nitric oxide (NO) production, and interleukin-8 
concentrations. During the early phase (that is, 4 to 
12  hours after induction of pneumonia), eNOS 
expression was increased, and this coincided with 
increased tissue levels of nitrotyrosine, poly(ADP-ribose), 
and NF-κB activation, whereas in the later phase (that is, 
until 24 hours of pneumonia), measurable NOS activity 
and NO produc  tion were related mainly to iNOS 
activation. Th   e authors’ ‘two-hit’ model of cotton smoke 
inhalation and subse  quent instillation of live bacteria is 
characterized by a hyperdynamic circulation, hypo  ten-
sion, tissue acidosis, and progressive impairment of gas 
exchange, lung mech  anics, and morphological alterations 
typical of acute lung injury. Furthermore, the model 
comprises resuscitation measures and thus allows the 
study of pathophysiological pathways in a clinically 
relevant, large-animal setting.
Numerous studies evaluated the NO-related mediator 
orchestra and highlighted the friend-and-foe character of 
excess NO formation [2]: NO not only is well established 
as a reactive nitrogen species (RNS), often referred to as a 
‘ﬁ  nal mediator’ of sepsis-induced hypotension, but also 
acts as a scavenger of reactive oxygen species (ROS), such 
as the superoxide radical. Th   is reaction, however, leads to 
the formation of the even more toxic peroxynitrite, which 
ultimately results in protein nitrosylation, DNA damage, 
and activation of poly(ADP-ribose) polymerase (PARP) 
[3]. Finally, the NO production rate depends on the 
stimulus and the species, and therefore rodent data 
cannot be transferred directly to the clinical scenario [4]. 
Endogenous NO production in large animals is much 
closer to that of human beings, but although increased 
NO production during sepsis is well established [2], these 
models yielded controversial results [5]. Th  e early and 
transient (within minutes) activation of PARP [3] would 
make PARP inhibition an attractive approach, but 
unfortunately medical care is usually not available during 
this very early phase. Moreover, the pathophysiological 
consequences of PARP-1 activation are opposed to its 
vital role in the maintenance of genomic integrity 
through its function in base excision repair, and the 
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during shock are still a matter of debate [6,7]. Th  erefore, 
PARP inhibitors are currently investigated in ischemia-
reperfusion, oncology, and diabetes rather than in sepsis 
or acute lung injury, and peroxynitrite-neutralizing 
agents are a tempting alternative [3,8]. Several studies 
explored the potential of selective inhibition of NOS 
isoforms under the assump  tions that nNOS and eNOS 
are constitutively producing homeostatic NO and that 
iNOS responds to acute stimuli with excessive NO 
production [2,5]. In fact, the crucial role of eNOS 
expression seems to be unequivocal: eNOS activation 
improved microvascular perfusion [9] and cardiac 
function [10] in rodents, and eNOS poly  morphism was 
associated with hypotension during human Gram-
negative sepsis [11]. Clearly, iNOS still seems to be a ‘bad 
guy’: several studies showed beneﬁ  cial eﬀ  ects of various 
selective iNOS inhibitors on hemo  dynamics, lung 
function, deranged microcirculatory per  fusion, coagula-
tion disorders, and visceral organ injury [12-14]. Recent 
data, however, suggest that nNOS activation may also 
assume major importance [15], and a combined approach 
using selective nNOS inhibition during the early phase (0 
to 12 hours) and iNOS inhibi  tion during the later phase 
(12 to 24 hours) yielded improved pulmonary function 
and attenuated nitrosative stress [16]. Finally, selective 
iNOS inhibition together with the ROS scavenger tempol 
also aﬀ  orded signiﬁ  cant protection, further emphasizing 
the close interaction of NO and oxidative/nitrosative 
stress [17]. Despite these encouraging results, nothing is 
simple or easy: in resuscitated murine septic shock, both 
genetic deletion and selective pharmacologic blockade of 
the iNOS were associated with markedly improved 
systolic contraction and catecholamine responsiveness 
but simultaneously deteriorated diastolic relaxation 
[18].
What can we learn from the study by Lange and 
colleagues [1]? Unfortunately, the authors did not report 
data on oxidative stress, so a complete overview of the 
whole RNS- and ROS-related mediator orchestra is only 
implicitly provided. Nevertheless, the authors add an 
important piece to the complex puzzle of the NO-related 
pathophysiological pathways: nitrosative stress (that is, 
increased nitrotyrosine and poly[ADP-ribose] levels) was 
aggravated only during the early phase up to 12 hours, 
whereas clear-cut increases in NOS activity, NO 
metabolites, and subsequently cytokines occurred only 
later on. Interestingly, in this experiment, in contrast to 
previous reports from the same group, nNOS synthesis 
was not increased. Finally, despite its inherent protective 
proper  ties, eNOS activation was also involved in the 
initiation of the septic response, and it remains to be 
elucidated whether this mirrors an adaptive or pathologic 
mechanism.
How can we translate these data to daily care? Usually, 
there are few chances to intervene during the very early, 
evolving phase of sepsis and acute lung injury, and at the 
time of full-blown sepsis, all members of the mediator 
orchestra are already playing their (un)coordinated, and 
unfortunately sometimes uncontrollable, concert. Th  ere 
are two ways to go from here, and both are worthy of 
being followed! First, though extremely time- and 
resource-consuming, long- or longer-term large-animal 
models with a more prolonged observation period (that 
is, days) are needed and will probably yield valuable clues 
to the design of clinical studies. Second, more studies on 
humans are warranted in order to better describe early 
and later phases of human sepsis in terms of NOS, 
peroxynitrite formation, and PARP activation. Th  ese  data 
might provide further evidence for drug and study design 
in the future. Lange and colleagues have the merit of 
having given the starting signal.
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